Felix Müller

Project Leader in Clinical Research at University of Basel

Data updated

Papers

26 publications

Trials

0 clinical trials

Research Footprint

Felix Müller appears in 26 tracked papers (2016–2026), most studied alongside LSD, MDMA and Psilocybin, across Healthy Volunteers, Anxiety Disorders and Neuroimaging & Brain Measures.

Most-cited paper: Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness A randomized, double-blind, placebo-controlled Phase II study (285 citations).

Frequent co-authors: Matthias Liechti, Stefan Borgwardt and Friederike Holze.

Background & Research

Dr. Felix Müller is a senior physician and researcher specializing in psychedelic-assisted therapy. His work at the University of Basel focuses on the efficacy of LSD and MDMA for a range of psychiatric conditions. He explores the potential of these substances to induce long-lasting antidepressant effects and investigates the neurobiological underpinnings of their therapeutic action.

Key Impact

Conducting trials on the therapeutic potential of LSD for anxiety, depression, and alcohol dependence.

26

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

52 collaborators· click a node to visit their profile

Full network →

Compounds

LSDMDMAPsilocybinPlacebo

Topics

Healthy VolunteersAnxiety DisordersNeuroimaging & Brain MeasuresDepressive DisordersMedicinal Chemistry & Drug DevelopmentSchizophreniaNeurocognitive DisordersPalliative & End-of-Life DistressInterpersonal Functioning & Social ConnectednessPTSDSafety & Risk ManagementPersonality & Trait FactorsBipolar DisorderSubstance Use Disorders (SUD)Major Depressive Disorder (MDD)Public Health, Prevention & Behaviour ChangeMicrodosingOlder AdultsCreativityTreatment-Resistant Depression (TRD)SuicidalityPersonality Disorders

Top Collaborators

Affiliations

Institutions, companies, and organisations Felix Müller is associated with.

University of Basel

academic

The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.

View stakeholder →